AI firm Aiforia and Mayo Clinic have exclusively licensed an AI model to improve prediction of colorectal cancer recurrence. The model analyses digitised tissue samples and combines this with clinical parameters to provide a personalised risk score. It will aid informed treatment decisions, potentially reducing unnecessary chemotherapy and better targeting high-risk patients to improve long-term outcomes. The Aiforia-Mayo Clinic collaboration also underlines a commitment to personalized medicine and continuous innovation.
Group-IB’s Threat Intelligence and Defence Centre Equip Undergraduates with Sophisticated Cybersecurity Technologies to Boost Threat Analysis and Enhance Cyber Resilience for Campus Start-ups
Hey there from the heart of the San Francisco Bay Area! It’s an absolute pleasure to have you back again for our chat on some
